ClinicalTrials.gg
RecruitingNCT07616700Updated Jun 1, 2026

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

A Phase 2 interventional study of HSK39297 200mgQD and HSK39297 300mgQD in IgA Nephropathy (IgAN), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 2 sites in China. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2025, registered Apr 2026).
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
59th of 109
73 · median 84
Started
2025
with 19 others
Phase 2
27 of 127
14 open now
Primary completion
2026-12
later than 19 of 72 live
Registered
110th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 59th largest by planned enrollment of the 109 interventional ones that give a count, is one of 20 that started in 2025, is one of 27 in phase 2, reaches primary completion later than 19 of the 72 other live ones, and was the 110th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This is a Phase II, multicenter, open-label study. Eligible subjects who have completed the HSK39297-202 study will be enrolled.Starting dose is 200 mg QD.Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains >1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.After the treatment period, subjects will enter the 4-week safety follow-up period.

03

Conditions studied

  • IgA Nephropathy (IgAN)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed the HSK39297-202 study and assessed by the investigator to have a favorable benefit-risk profile for 200 mg QD HSK39297.
  2. ≥30 mL/min/1.73 m² at screening (calculated by CKD-EPI 2021 equation).
  3. Able to maintain optimized, stable background therapy with RAS blockers, SGLT2 inhibitors, endothelin receptor antagonists, or hydroxychloroquine during the study.
  4. Vaccinated against Neisseria meningitidis and Streptococcus pneumoniae as required in the previous study (booster if needed).
  5. Fertile females: negative serum pregnancy test; highly effective from signing until 30 days after last dose.

    Fertile males: highly effective contraception from signing informed consent until 90 days after last dose.

  6. Voluntarily provided written informed consent and able to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected hereditary or acquired complement deficiency.
  2. Active primary or secondary immunodeficiency.
  3. History of bone marrow / hematopoietic stem cell or solid organ transplantation.
  4. within the past 5 years (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).
  5. History of recurrent invasive infections caused by encapsulated bacteria (e.g., N. meningitidis, S. pneumoniae) or Mycobacterium tuberculosis.
  6. Severe concomitant diseases judged by the investigator to be incompatible with study participation.
  7. Suspected to the product or its class.
  8. Pregnant or lactating females.
  9. Other conditions that may interfere with the study or increase subject risk.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (estimated)

Study arms

  • Active comparator
    200mg QD

    Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains \>1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.

    Drug: HSK39297 200mgQD · Drug: HSK39297 300mgQD

Interventions

  • Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains \>1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.

  • Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains \>1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) during treatment.

    Time frame: 48 weeks

Secondary outcomes

  1. Ratio of 24-h urine protein-to-creatinine ratio (24h-UPCR) from baseline every 12 weeks during treatment

    Time frame: 48 weeks

  2. Ratio of 24-h urine protein excretion (24h-UPE) from baseline every 12 weeks during treatment

    Time frame: 48 weeks

  3. Change in estimated glomerular filtration rate (eGFR) from baseline every 24 weeks during treatment.

    Time frame: 48 weeks

  4. Proportion of subjects with hematuria every 12 weeks during treatment.

    Time frame: 48 weeks

  5. Change in Functional Assessment of Chronic Illness FACIT-F(Functional Assessment of Chronic Illness Therapy-Fatigue)score from baseline every 12 weeks during treatment

    The scale consists of 13 items, assessing patients' fatigue levels over the past seven days as well as fatigue impacts on cognition, physical function, psychology and social interaction. The total score is the sum of scores for all items, ranging from 0 to 52. A higher score indicates a lower degree of fatigue.

    Time frame: 48 weeks

Other outcomes

  1. Pharmacokinetic (Cmax) of HSK39297 at 300 mg QD

    Exploratory Endpoint

    Time frame: 48 weeks

  2. Pharmacokinetic (Tmax) of HSK39297 at 300 mg QD

    exploratory endpoint

    Time frame: 48 weeks

  3. Pharmacokinetic (AUC0-tau) of HSK39297 at 300 mg QD

    exploratory endpoint

    Time frame: 48 weeks

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Jun 1, 2026
StartActual
Aug 25, 2025
Primary completionEst.
Dec 5, 2026
CompletionEst.
Dec 26, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07616700
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Aug 25, 2025
Primary completion
Dec 5, 2026 (estimated)
Completion
Dec 26, 2026 (estimated)
Last update
Jun 1, 2026

Study contacts

li fangqiong Li
Contact
lifangq@haisco.com
+86028-67258840

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39297

Start the discussion